PharmaMar
Biotechnology Research • 
Colmenar Viejo, Community of Madrid, Spain • 201-500 Employees
Company overview
| Headquarters | Avda. De los Reyes, 1, Colmenar Viejo, Madrid 28770, ES |
| Phone number | +3416178683797 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Oncology, Drug Discovery, Drug Development, Pharmaceutical Marketing |
| Founded | 1986 |
| Employees | 201-500 |
| Socials |
Key Contacts at PharmaMar
Christophe Chevreau
Associate Director Business Development, Licensing And Alliance Management
Ines Perez Calleja
Global Quality Director
Juan Gómez Pulido
Secretario General Y Del Consejo/ General Counsel & Secretary Of The Board Of Directors
Chelo Tudela
Associate Director Regulatory Affairs
Javier Garrido
Country Director Switzerland
Juan Carnicero Gómez
Sustainability Director
Pablo Banos
Supply Chain Associate Director
Elisa Borrego Garcia
Public Affairs Director
Belén Sopesén
Director Of Corporate Affaires
Ana Ruiz Madera
Associate Director Regulatory Affairs
PharmaMar Email Formats
PharmaMar uses 5 email formats. The most common is {first name}{last name} (e.g., johndoe@pharmamar.com), used 67% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@pharmamar.com | 67% |
{first initial}{last name} | jdoe@pharmamar.com | 18.8% |
{first initial}{second initial} | jo@pharmamar.com | 8.6% |
{last name}{last name} | doedoe@pharmamar.com | 1.5% |
{last name}{second initial} | doeo@pharmamar.com | 1% |
About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin. PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, PM14, PM534 and PM54. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.
PharmaMar revenue & valuation
| Annual revenue | $174,600,000 |
| Revenue per employee | $380,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $558,600,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
PharmaMar has 227 employees across 15 departments.
Departments
Number of employees
Funding Data
PharmaMar has never raised funding before.
PharmaMar Tech Stack
Discover the technologies and tools that power PharmaMar's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
JavaScript libraries
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
Analytics
Translation
WordPress plugins
Tag managers
Indonesia
United States
Canada
Israel
India
SwedenFrequently asked questions
4.8
40,000 users
